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Abstract
We propose a class of two-sample statistics for testing the equality of proportions and the equality of survival func-
tions. We build our proposal on a weighted combination of a score test for the difference in proportions and a
Weighted Kaplan-Meier statistic-based test for the difference of survival functions. The proposed statistics are fully
non-parametric and do not rely on the proportional hazards assumption for the survival outcome. We present the
asymptotic distribution of these statistics, propose a variance estimator and show their asymptotic properties under
fixed and local alternatives. We discuss different choices of weights including those that control the relative rele-
vance of each outcome and emphasize the type of difference to be detected in the survival outcome. We evaluate
the performance of these statistics with a simulation study, and illustrate their use with a randomized phase III can-
cer vaccine trial. We have implemented the proposed statistics in the R package SurvBin, available on GitHub
(https://github.com/MartaBofillRoig/SurvBin).
Keywords: Clinical Trials; Mixed Outcomes; Multiple Endpoints; Multiple testing; Non-Proportional Hazards;
Survival Analysis; Weighted Mean survival test.
1. Introduction
In many clinical studies, two or more endpoints are investigated as co-primary aiming to provide a comprehensive
picture of the treatment’s benefits and harms. Survival analysis has often been the sharp focus of clinical trial research.
However, when there is more than one event of interest, the time until the appearance of the event is not always the
unique center of attention; often the occurrence of an event over a fixed time period is as well an outcome of interest.
In the context of cancer immunotherapies trials, short-term binary endpoints based on the tumor size, such as
objective response, are common in early-phase trials, whereas overall survival remains the gold standard in late-phase
trials (Wilson et al., 2015, Ananthakrishnan and Menon, 2013). Since traditional oncology endpoints may not capture
the clinical benefit of cancer immunotherapies, the idea of looking at both tumor response and survival has grown
from the belief that together may achieve a better characterization of the clinical response (Thall, 2008).
Several authors have considered both objective response and overall survival as co-primary endpoints in cancer
trials. Lai and Zee ((2015)) proposed a single-arm phase II trial design with tumor response rate and a time-to-event
outcome, such as overall survival or progression free survival. In their design, the dependence between the probability
of response and the time-to-event outcome is modeled through a Gaussian copula. Lai, Lavori, and Shih ((2012))
proposed a two-step sequential design in which the response rate and the time to the event are jointly modeled. Their
approach relates the response rate and the time to the event by means of a mixture model build on the basis of the Cox
proportional hazards model assumption. Chen and Wang ((2020)) presented a joint model for binary marker responses
and survival outcomes for clustered data. They based the statistical inference on a multivariate penalized likelihood
method and estimate the standard errors using a jackknife resampling method.
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An additional challenge in immunotherapy trials lies in the fact that delayed effects are likely to be found, bringing
the need of alternative methods accounting for the non-proportionality of the hazards (Mick and Chen, 2015). Statis-
tics that look at differences between integrated weighted survival curves, such as those defined by Pepe and Fleming
((1989, 1991)) and extended by Gu, Follmann, and Geller ((1999)), are better suited to detect early or late survival
differences and do not depend on the proportional hazards assumption. In this paper, we aim to propose a class of
two-sample statistics that could be used in seamless phase II/III design to jointly evaluate the efficacy on binary and
survival endpoints, even in the presence of delayed treatment effects.
The problem of how to analyze multiple outcomes has been widely discussed in the literature (Dmitrienko and
Agostino, 2013, Alosh, Bretz, and Huque, 2014). The classical approach is to restrict the attention to multiple testing
procedures that control the probability of one or more false rejections, the so-called familywise error rate, which guar-
antee the nominal significance level (Lehmann and Romano, 2012). However, classical multiple testing procedures
based on correcting the significance level (e.g, Bonferroni procedure (Bland and Altman, 1995)) may not be appropri-
ate since they do not take into account the potential association between the binary and survival outcomes and might
lead to conservative designs.
Other alternative approaches have been developed allowing for the joint distribution of test statistics. O’Brien
((1984)) and Pocock, Geller, and Tsiatis ((1987)) proposed global test statistics through the sum of individual statis-
tics. O’Brien ((1984)) developed a generalized least squares method by combining multiple statistics into a sin-
gle hypothesis test when variables are normally distributed; whereas Pocock, Geller, and Tsiatis ((1987)) extended
O’Brien’s work to asymptotically normal test statistics. Hothorn, Bretz, and Westfall ((2008)) and Pipper, Ritz, and
Bisgaard ((2012)) approached the problem of testing multiple hypothesis using parametric and semi-parametric mod-
els. Hothorn, Bretz, and Westfall ((2008)) used the limiting distribution of the parameter estimators to build upon the
corresponding test statistics and their joint distribution. Based on that, their approach corrects the significance level
by means of the simultaneous asymptotic normality of the test statistics. Pipper, Ritz, and Bisgaard ((2012)) proposed
a procedure for evaluating the efficacy in trials with multiple endpoints of different types. Their procedure is based
on simultaneous asymptotic normality of effect estimators from the single-models for each endpoint together with
multiple testing adjustments.
Extensive research has been done on joint modeling of longitudinal measurements and survival data (comprehen-
sive overviews can be found in Tsiatis and Davidian ((2004)), Rizopoulos ((2012)) and Papageorgiou et al. ((2019))).
In most cases, the primary focus is on characterizing the association between the longitudinal and event time pro-
cesses. The common framework is to relate the time-to-event and longitudinal outcomes through the proportional
hazard model. Nevertheless, the relationship between binary response at a specific time point and survival outcome
has received less attention (Chen and Wang ((2020))).
In this paper, we have followed the idea launched by Pocock, Geller, and Tsiatis ((1987)) of combining multiple
test statistics into a single hypothesis test. Specifically, we propose a class of statistics based on a weighted sum
of a difference in proportions test and a weighted Kaplan-Meier test-based for the difference of survival functions.
Our proposal adds versatility into the study design by enabling different follow-up periods for each endpoint, and
flexibility by incorporating weights. We define these weights to specify unequal priorities to the different endpoints
and to anticipate the type of time-to-event difference to be detected.
This article is organized as follows. In Section 2 we present the class of statistics for binary and time-to-event
outcomes. In Section 3 we set out the assumptions and present the large sample distribution theory for the proposed
statistics. In Section 4 we introduce different weights and discuss about their choice. We give an overview of our R
package SurvBin in Section 5 and illustrate our proposal with a recent immunotherapy trial in Section 6. In Section 7
we evaluate the performance of these statistics in terms of the significance level with a simulation study. We conclude
with a discussion.
All the required functions to use these statistics have been implemented in R and have been made available at:
https://github.com/MartaBofillRoig/SurvBin.
2. A general class of binary and survival test statistics
Consider a study comparing two groups, control group (i = 0) and intervention group (i = 1), each composed of
n(i) individuals, and denote by n = n(0) +n(1) the total sample size. Suppose that both groups are followed over the time
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interval [0, τ] and are compared on the basis of the following two endpoints: the occurrence of an event εb before τb
(0 < τb ≤ τ), and the time to a different event εs within the interval [τ0, τ] (0 ≤ τ0 < τ). For the i-th group (i = 0, 1),
let p(i) (τb) be the probability of having the event εb before τb, and S (i)(·) be the survival function of the time to the
event εs.
We consider the problem of testing simultaneously Hb,0: p(0)(τb) = p(1)(τb) and Hs,0: S (0)(t) = S (1)(t),∀t ∈ [τ0, τ],
aiming to demonstrate either a higher probability of the occurrence of εb or an improved survival with respect to εs in
the intervention group. The hypothesis problem can then be formalized as:
H0 : p(0)(τb) = p(1)(τb) and S (0)(t) = S (1)(t), ∀t ∈ [τ0, τ]
H1 : p(0)(τb) < p(1)(τb) or S (0)(t) ≤ S (1)(t), ∀t ∈ [τ0, τ],
∃t ∈ [τ0, τ], S (0)(·) < S (1)(·)
(1)
We propose a class of statistics –hereafter called L-class– as a weighted linear combination of the difference of
proportions statistic for the binary outcome and the integrated weighted difference of two survival functions for the
time-to-event outcome, as follows,
Uωn (τ0, τb, τ; Qˆ) = ωb ·
Ub,n (τb)
σˆb
+ ωs · Us,n(τ0, τ; Qˆ)
σˆs
(2)
for some real numbers ωb, ωs ∈ (0, 1), such that ωb + ωs = 1, and where:
Ub,n (τb) =
√
n(0)n(1)
n
(
pˆ(1) (τb) − pˆ(0) (τb)
)
(3)
Us,n(τ0, τ; Qˆ) =
√
n(0)n(1)
n
(∫ τ
τ0
Qˆ(t) ·
(
Sˆ (1)(t) − Sˆ (0)(t)
)
dt
)
(4)
denoting by pˆ(i)(τb) the estimated proportion of events εb before τb, and by Sˆ (i)(·) the Kaplan-Meier estimator of S (i)(·)
for group i. The estimates σˆ2b and σˆ
2
s are such that converge in probability to σ
2
b and σ
2
s , respectively, as n → +∞,
where σ2b and σ
2
s represent the variances of Ub,n (τb) and Us,n(τ0, τ; Qˆ), respectively. Both theoretical and estimated
expressions for the variances of Ub,n (τb) and Us,n(τ0, τ; Qˆ) will be given in Section 3 (see equations (7, 8) for the
theoretical expressions and (12, 13) for the estimates). The term Qˆ(·) is a possibly random function which converges
pointwise in probability to a deterministic function Q(·). For ease of notation, and letting ω = (ωb, ωs), we will
suppress the dependence on τ0, τb, τ and use instead Uωn (Qˆ), Ub,n, Us,n(Qˆ). Note that pˆ(i)(τb), Sˆ (i)(·), σˆb and σˆs depend
on the sample size n(i), but it has been omitted in notation for short.
The weights ω control the relative relevance of each outcome -if any- and the random weight function Qˆ(·) serves
two purposes: to specify the type of survival differences that may exist between groups and to stabilize the variance
of the difference of the two Kaplan-Meier functions. Some well-known special cases of Qˆ(·) are:
(i) Qˆ(t) = Gˆ(t−), where Gˆ(t−) is the pooled Kaplan-Meier estimator for the censoring distribution. This choice of
Qˆ(t) down-weights the contributions on those times where the censoring is heavy.
(ii) Qˆ(t) = Sˆ (t−)ρ · (1 − Sˆ (t−))γ, where ρ, γ ≥ 0 and Sˆ (t−) is the pooled Kaplan-Meier estimator for the survival
function. This Qˆ(t) corresponds to the weights of the Gp,q family (Fleming and Harrington, 1991). Then,
for instance, if ρ = 1 and γ = 0, Qˆ(t) emphasizes early differences between survival functions; whereas late
differences could be highlighted with ρ = 0 and γ = 1.
(iii) Qˆ(t) = Y¯(t−), where Y¯(t−) denotes the number of individuals at risk of εs at time t. In this case Qˆ(t) accentuates
the information at the beginning of the survival curve allowing early failures to receive more weight than later
failures.
We state the precise conditions for the weight function Qˆ(·) in Section 3 and postpone the discussion about the choice
of Qˆ(·) and ω = (ωb, ωs) to Section 4.
The statistics in the L-class are defined for different follow-up configurations based on different choices of: the
overall follow-up period, τ; the time where the binary event is evaluated, τb; and the origin time for the survival
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outcome, τ0; taking into account that 0 < max{τ0, τb} < τ. There are however no restrictions on whether or not
these periods overlap and, if they do, how much and when. We illustrate two different situations with different
configurations for τ0, τb, τ in Figure 1. The first case is exemplified by an HIV therapeutic vaccination study where
safety-tolerability response (binary outcome) and time-to-viral rebound (survival outcome) are outcomes of interest.
Whereas the safety-tolerability is evaluated at week 6 (τb = 6), the time-to-viral rebound is evaluated from week 6 to
18 (τ0 = 6 and τ = 18) (De Jong et al., 2019). The second example in the area of immunotherapy trials includes a
binary outcome (objective response), evaluated at month 6, and overall survival, evaluated from randomization until
year 4 (τ0 = 0, τb = 0.5 and τ = 4) (Hodi et al., 2019).
The L-class statistics includes several statistical tests. If τ0 = 0, τb = τ and ωb = ωs, then, Uωn (Qˆ) corresponds
to the global test statistic proposed by Pocock, Geller, and Tsiatis ((1987)). If εb = εs, τ0 = τb, and ωb = ωs, the
statistic Uωn (Qˆ) is the equivalent of the linear combination test of Logan, Klein, and Zhang ((2008)) when there is no
censorship until τb for testing for differences in survival curves after a pre-specified time-point.
3. Large sample results
In this section, we derive the asymptotic distribution of theL-class of statistics given in (2) under the null hypothe-
sis and under contiguous alternatives, present an estimator of their asymptotic variance, and discuss the consistency of
the L-statistics against any alternative hypothesis of the form of H1 in (1). We start the section with the conditions we
require for the L-class of statistics. In order to make the paper more concise and more readable, proofs and technical
details are in the Supplementary material.
3.1. Further notation and Assumptions
We consider two independent random samples of n(i) (i = 0, 1) individuals and for each we denote the binary
response by Xi j = I{εb has occurred}, the time to εs by Ti j and the censoring time by Ci j for j = 1, ..., n(i) and where
I{·} is the usual 0/1 indicator function. Assuming that Ti j is non-informatively right-censored by Ci j, the observable
data are summarized by {Xi j,Ti j ∧Ci j, δi j}, where δi j = I{Ti j ∧Ci j = Ti j} and a ∧ b = min(a, b). Suppose as well that
Xi j is independent of Ci j and that the occurrence of the survival and censoring times, Ti j and Ci j, does not prevent to
assess the binary response, Xi j.
Denote by G(i)(·) and Gˆ(i)(·) the censoring survival function and the Kaplan-Meier estimator for the censoring
times, respectively. As we will see in the next section, the distribution of the L-statistics relies, among others, on the
survival function for those patients who respond to the binary endpoint. We then introduce here the survival function
for responders as S (i)X (t) = P(Ti j > t|Xi j = 1) (t > τb).
Furthermore we assume that: (i) S (i)(τ) > 0, S (i)X (τ) > 0 and G
(i)(τ) > 0; (ii) the limiting fraction of the total
sample size is non-negligible, i.e., lim
n→+∞n
(i)/n = pi(i) ∈ (0, 1); and (iii) Q(·) is a nonnegative piecewise continuous with
finitely discontinuity points. For all the continuity points in [0, τ], Qˆ(t) converges in probability to Q(t) as n → +∞.
Moreover, Qˆ(·) and Q(·) are functions of total variation bounded in probability.
Finally, we introduce the counting process N¯(i)(t) =
∑n(i)
j=1 Ni j(t) =
∑n(i)
j=1 I{Ti j ∧ Ci j ≤ t, δi j = 1} as the number of
observed events that have occurred by time t for the i-th group (i = 0, 1) and Y¯ (i)(t) =
∑n(i)
j=1 Yi j(t) =
∑n(i)
j=1 I{Ti j∧Ci j ≥ t}
as the number of subjects at risk at time t for the i-th group. We define y(i)(s) = E
(
Yi j(s)
)
and suppose that y(i)(τ) > 0.
Remark: Throughout the paper and to refer to the group i (i = 0, 1), we will use subindexes for the individual
observations and stochastic processes, as in Xi j, while we will use superindexes in parentheses for the functions and
parameters, as in S (i)(·).
3.2. Asymptotic distribution
In order to derive the asymptotic distribution of the statistic Uωn (Qˆ), we first note that Uωn (Qˆ) can be approximated
by Uωn (Q), the same statistic with the weights replaced by its deterministic function.
Lemma 3.1. Let Uωn (Q) be the statistic defined by:
Uωn (Q) = ωb ·
Ub,n
σˆb
+ ωs · Us,n(Q)
σˆs
(5)
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where Ub,n is the statistic given in (3) and Us,n(Q) is the statistic given in (4) with Qˆ(t) replaced by Q(t), that is:
Us,n(Q) =
√
n(0)n(1)
n
(∫ τ
τ0
Q(t) ·
(
Sˆ (1)(t) − Sˆ (0)(t)
)
dt
)
(6)
for some real numbers ωb, ωs ∈ (0, 1), such that ωb +ωs = 1, and for a function Q(·) satisfying the conditions outlined
in Section 3.1. Then, the L-statistic Uωn (Qˆ), given in (2), can be written as:
Uωn (Qˆ) = U
ω
n (Q) + ωs ·
En
σˆs
where
En =
√
n(0)n(1)
n
∫ τ
τ0
(Qˆ(t) − Q(t)) · (Sˆ (1)(t) − Sˆ (0)(t))dt
converges in probability to 0. Hence, the asymptotic distribution of the statistic Uωn (Q) is the same as that of Uωn (Qˆ).
Roughly speaking, thanks to this theorem we can ignore the randomness of Qˆ(·) and use Uωn (Q) to obtain the
limiting distribution of Uωn (Qˆ). In what follows, we state the asymptotic distributions under the null hypothesis in
Theorem 3.2 and under a sequence of contiguous alternatives in Theorem 3.3.
Theorem 3.2. Let Uωn (Qˆ) be the statistic defined in (2). Under the conditions outlined in 3.1, if the null hypothesis
H0 : Hs,0 ∩ Hb,0 holds, Uωn (Qˆ) converges in distribution, as n→ +∞, to a normal distribution as follows:
Uωn (Qˆ)→ N
(
0, ω2b + ω
2
s + 2ωbωs ·
σbs
σb · σs
)
where σ2b, σ
2
s stand for the variances of Ub,n and Us,n(Q), respectively, and σbs is the covariance between Ub,n and
Us,n(Q). Their corresponding expressions are given by:
σ2b =
∑
i=0,1
(
1 − pi(i))p(i) (τb) (1 − p(i) (τb)) (7)
σ2s = −
∑
i=0,1
(
1 − pi(i)) ∫ τ
τ0
(K(i)τ (t))2
(S (i)(t))2G(i)(t)
dS (i)(t) (8)
σbs =
∑
i=0,1
(
1 − pi(i)) · (I{τmax = τb} · ∫ τb
τ0
K(i)τb (t)
S (i)(t)
·
(
p(i)N (t) − p(i) (τb)
)
dS (i)(t)
+
∫ τ
τmax
K(i)τ (t)
S (i)(t)
· p(i) (τb)
(
dS (i)X (t) − dS (i)(t)
) (9)
where τmax = max(τ0, τb), K
(i)
τ∗ (t) =
∫ τ∗
t Q(u)S
(i)(u)du (τ∗ = τ or τb),
p(i)N (t) = P(Xi j = 1|dNi j(t) = 1), and S (i)X (t) = P(Ti j > t|Xi j = 1) for i = 0, 1.
Recall that σ2b, σ
2
s , and σbs depend on τ0, τb, τ, but we omit them for notational simplicity.
Theorem 3.3. Let Uωn (Qˆ) be the statistic defined in (2). Under the conditions outlined in 3.1., consider the following
sequences of contiguous alternatives for both binary and time-to-event hypotheses satisfying, as n→ +∞:
√
n(p(1)n − p(0))→ g
and √
n(S (1)n (t) − S (0)(t))→ G(t)
for some constant g ∈ R+ and bounded function G(·) ∈ R+, and ∀t ∈ [τ0, τ]. Then, under contiguous alternatives of
the form:
H1,n :
√
n(p(1)n − p(0)) = g and
√
n(S (1)n (t) − S (0)(t)) = G(t), ∀t ∈ [τ0, τ] (10)
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we have that:
Uωn (Qˆ)→ N
(
ωbg + ωs
∫ τ
τ0
Q(t)G(t)dt, ω2b + ω2s + 2ωbωs
σbs
σb · σs
)
in distribution as n→ +∞, where σ2b, σ2s and σbs are given in (7), (8) and (9), respectively.
The covariance in (9) involves the conditional probabilities S (i)X (t) and p
(i)
N (t), while S
(i)
X (t) represents the survival
function for responders –patients that have had the binary event εb–, p
(i)
N (t) stands for the probability of being a
responder among patients experiencing εs at t. Also note that, if τb < τ0, the survival experience starts after the binary
event has been evaluated and only involves the second integral in (9).
We notice that the efficiency of the L-statistics, Uωn (Qˆ), under contiguous alternatives is driven by the non-
centrality parameter µc = ωbg + ωs
∫ τ
τ0
Q(t)G(t)dt, that is, by the sum of the weighted non-centrality parameters
of Ub,n and Us,n(Qˆ).
3.3. Variance estimation and consistency
We now describe how to use the L-statistics to test H0 versus H1 given in (1). Theorem 3.4 gives a consistent
estimator of the asymptotic variance of Uωn (Qˆ), and Theorem 3.5 presents the standardized L-statistics to test H0 :
Hs,0 ∩ Hb,0.
Theorem 3.4. Let Uωn (Qˆ) be the statistic defined in (2), and let σ2b, σ
2
s and σbs be the variances and covariance
given in (7), (8) and (9), respectively. The asymptotic variance of Uωn (Qˆ), given in Theorem 3.2, can be consistently
estimated by:
V̂ar(Uωn (Qˆ)) = ω
2
b + ω
2
s + 2ωbωs
σˆbs
σˆb · σˆs (11)
where σˆb, σˆs, and σˆbs denote the estimates of σb, σs and σbs, and are given by:
σˆ2b = pˆ (τb) (1 − pˆ (τb)) (12)
σˆ2s = −
∫ τ
τ0
(Kˆτ(t))2
Sˆ (t)Sˆ (t−) ·
n(0)Gˆ(0)(t−) + n(1)Gˆ(1)(t−)
Gˆ(0)(t−)Gˆ(1)(t−) dSˆ (t) (13)
σˆbs = −
∫ τb
τ0
Kˆτb (t)
∑
i=0,1
n − n(i)
n
· λˆ(i)X,T (t)dt +
pˆ (τb) · dSˆ (t)
Sˆ (t)

+
∫ τ
τb
Kˆτ(t) · pˆ (τb)
Sˆ (t−)
− Sˆ (t−) · dSˆ (t)Sˆ (t) + ∑i=0,1 n − n
(i)
n
· Sˆ
(i)
X (t−) · dSˆ (i)X (t)
Sˆ (i)X (t)
 (14)
where Kˆτ∗ (t) =
∫ τ∗
t Qˆ(u)Sˆ (u)du (τ∗ = τ or τb), Sˆ
(i)
X (t) is the Kaplan-Meier estimator of S
(i)
X (t); and λˆ
(i)
X,T (t) is the
estimator of λ(i)X,T (t) = limdt→0 P(Xi j = 1, t ≤ Ti j < t+dt|Ti j > t)/dt. Kernel-density methods are used in the estimation
of λ(i)X,T (t).
Theorem 3.5. Let Uωn (Qˆ) be the statistic defined in (2), and let V̂ar(Uωn (Qˆ)) be the variance estimator given in (11).
Consider the global null hypothesis H0 ((1)) and let the normalized statistic of Uωn (Qˆ) be:
Uωn (Qˆ)
/√
V̂ar(Uωn (Qˆ)) (15)
Then, the statistic defined in (15) converges in distribution to a standard normal distribution. Moreover, for positive
Q(·), the statistic is consistent against any alternative hypothesis of the form of H1 in (1) which contemplate differences
and stochastic ordering alternatives for the binary and time-to-event outcomes, respectively.
We are presenting here a pooled variance estimator of Uωn (Qˆ). An unpooled variance estimator is proposed in the
Supplementary Material.
Theorem 3.5 can be used to test the global null hypothesis H0 : Hs,0 ∩Hb,0 by comparing Uωn (Qˆ)
/√
V̂ar(Uωn (Qˆ)) to
a standard normal distribution.
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4. On the choice of weights
An important consideration when applying the statistics proposed in this paper is the choice of the weight func-
tions. TheL-class of statistics involves the already mentioned random weight function Qˆ(t) and deterministic weights
ω = (ωb, ωs). These weights are defined according to different purposes and have different roles into the statistic
Uωn (Q). In this section, we include different weights and discuss some of their strengths as well as shortcomings. The
list provided is not exhaustive, other weights are possible and might be useful in specific circumstances.
4.1. Choice of ω = (ωb, ωs)
The purpose of the weights ω is to prioritize the binary and the time-to-event outcomes. They have to be specified
in advance according to the research questions. Whenever the two outcomes are equally relevant, we should choose
ωb = ωs = 0.5. In this case the statistics will be optimal whenever the standardized effects on both outcomes coincide.
4.2. Choice of Qˆ(·)
The choice of Qˆ(·) might be very general as long as Qˆ(·) converges in probability to a function Q(·), and both Qˆ(·)
and Q(·) satisfy the conditions outlined in 3.1. In this section, we center our attention on a family of Qˆ(·) weights of
the form:
Qˆ(t) = fˆ (t) · vˆ(t),
where: (i) fˆ (·) is a data-dependent function that converges, in probability to f (·), a nonnegative piecewise continuous
function with bounded variation on [0, 1]. The term fˆ (t) takes care of the expected differences between survival
functions and can be used as well to emphasize some parts of the follow-up according to the time-points (τ0, τb, τs);
(ii) the weights vˆ(·) converge in probability to a deterministic positive bounded weight function v(·). The main purpose
of the weight vˆ(t) is to ensure the stability of the variance of the difference of the two Kaplan-Meier functions. To do
so, we make the additional assumption that:
|v(t)| ≤ Γ ·G(i)(t)1/2+δ and |vˆ(t)| ≤ Γ · Gˆ(i)(t)1/2+δ
for all t ∈ [τ0, τ], i = 0, 1 and for some constants Γ, δ > 0.
Different choices of fˆ (t) yield other known statistics. For instance, if f (·) = 1, Us,n(Qˆ) corresponds to the Weighted
Kaplan-Meier statistics (Pepe and Fleming, 1989, 1991). Whenever fˆ and vˆ correspond to the weights (17) and (16),
respectively, introduced below, we have the statistic proposed by Shen and Cai ((2001)). Furthermore, note that
the weight functions of the form Qˆ(t) = fˆ (t) · vˆ(t) are similar to those proposed by Shen and Cai ((2001)); while
they assume that fˆ is a bounded continuous function, we assume that fˆ (·) is a nonnegative piecewise continuous
function with bounded variation on [0, 1], and instead of only considering the Pepe and Fleming weight function
corresponding to (17), we also allow for different weight functions vˆ(t). Finally, if the random quantity Qˆ(t) is omitted
Us,n(Qˆ) corresponds to the difference of restricted mean survival times from τ0 to τ.
In what follows, we outline different choices of vˆ(t) and fˆ (t), together with a brief discussion for each one:
• We require vˆ(t) to be small towards the end of the observation period if censoring is heavy. The usual weight
functions vˆ(t) involve Kaplan-Meier estimators of the censoring survival functions. The most common weight
functions are:
vˆc(t) =
nGˆ(0)(t−)Gˆ(1)(t−)
n(0)Gˆ(0)(t−) + n(1)Gˆ(1)(t−) (16)
and vˆ√(t) =
√
vˆc(t), both proposed by Pepe and Fleming. Among other properties, vˆc(·) has been proved to be
a competitor to the logrank test for the proportional hazards alternative (Pepe and Fleming, 1989). Note that
if the censoring survival functions are equal for both groups and the sampling design is balanced (n(0) = n(1)),
then, the differences in Kaplan-Meier estimators are weighted by the censoring survival function, that is, w(t) =
C(t) = C(i)(t) for i = 0, 1. Also note that w(t) = 1 for uncensored data.
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• Analogously to Fleming and Harrington ((1991)) statistics, fˆ (t) could be used to specify the type of expected
differences between survival functions. That is, if we set:
f (Sˆ (t−)) = Sˆ (t−)ρ(1 − Sˆ (t−))γ, ρ, γ ≥ 0 (17)
the choice ρ > 0, γ = 0 leads to a test to detect early differences, while ρ = 0, γ > 0 leads to a test to detect late
differences; and ρ = γ = 0 leads to a test evenly distributed over time and corresponds to the weight function of
the logrank.
• In order to put more emphasis on those times after the binary follow-up period we might consider:
f (t) =
a, t < τb1 − a, t ≥ τb
for a < 0.5.
5. Implementation
We have developed the SurvBin package to facilitate the use of the L-statistics and is now available on GitHub.
The SurvBin package contains three key functions: lstats to compute the standardizedL-statistic, Uωn (Qˆ)/√V̂ar(Uωn (Qˆ));
and bintest and survtest for the univariate binary and survival statistics (3) and (4), Ub,n (τb)
/
σˆb and Us,n(τ0, τ; Qˆ)
/
σˆs,
respectively. The SurvBin package also provides the functions survbinCov, that can be used to calculate σˆbs; and
simsurvbin for simulating bivariate binary and survival data.
The main function lstats can be called by:
lstats(time, status, binary, treat, tau0, tau, taub, rho, gam, eta, wb, ws, var est)
where time, status, binary and treat are vectors of the right-censored data, the status indicator, the binary
data and the treatment group indicator, respectively; tau0, tau, taub denote the follow-up configuration; wb, ws
are the weights ω; rho, gam, eta are scalar parameters that controls the weight Qˆ(t) which is given by Qˆ(t) =
Gˆ(t−)η · Sˆ (t−)ρ · (1 − Sˆ (t−))γ; and var est indicates the variance estimate to use (pooled or unpooled).
In this work, we estimate λ(i)X,T (t) by means of the Epanechnikov kernel function, and the local bandwidth selec-
tion and the boundary correction described by Muller and Wang ((1994)) by using the muhaz package (Hess and
Gentleman, 2019).
6. Examples
Melanoma has been considered a good target for immunotherapy and its treatment has been a key goal in recent
years. Here we consider a randomized, double-blind, phase III trial whose primary objective was to determine the
safety and efficacy of the combination of a melanoma immunotherapy (gp100) together with an antibody vaccine
(ipilimumab) in patients with previously treated metastatic melanoma (Hodi et al., 2019). Despite the original endpoint
was objective response rate at week 12, it was amended to overall survival and then considered secondary endpoint.
A total of 676 patients were randomly assigned to receive ipilimumab plus gp100, ipilimumab alone, or gp100 alone.
The study was designed to have at least 90% power to detect a difference in overall survival between the ipilimumab-
plus-gp100 and gp100-alone groups at a two-sided α level of 0.05, using a log-rank test. Cox proportional-hazards
models were used to estimate hazard ratios and to test their significance. The results showed that ipilimumab with
gp100 improved overall survival as compared with gp100 alone in patients with metastatic melanoma. However, the
treatment had a delayed effect and an overlap between the Kaplan-Meier curves was observed during the first six
months. Hence, the proportional hazards assumption appeared to be no longer valid, and a different approach would
had been advisable.
In order to illustrate our proposal, we consider the comparison between the ipilimumab-plus-gp100 and gp100-
alone groups based on the overall survival and objective response as co-primary endpoints of the study. For this
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purpose, we have reconstructed individual observed times by scanning the overall survival Kaplan-Meier curves re-
ported in Figure 1A of Hodi et al. ((2019)) using the reconstructKM package (Sun, 2020) (see Figure 2), and,
afterwards, we have simulated the binary response to mimic the percentage of responses obtained in the study.
Using the data obtained, we employ the L-statistic by means of the function lstats in the SurvBin package.
To do so, we need to specify the weights (Qˆ, ω) to be used, and the time-points (τ0, τb, τ). In our particular case, we
take τ0 = 0, τb = 0.5, τ = 4 according to the trial design, choose Qˆ(t) = Gˆ(t−) · (1 − Sˆ (t−)) to account for censoring
and delayed effects in late times, and (ωb, ωs) = (0.25, 0.75) to emphasize the importance of overall survival over
objective response. The results are summarized in Figure 2.
Since we obtained Uωn (Qˆ) = 4.10 > zα=0.05, we have a basis to reject H0 and conclude that the ipilimumab either
improved overall survival or increased the percentages of tumor reduction in patients with metastatic melanoma, or
both.
7. Simulation study
7.1. Design
We have conducted a simulation study to evaluate our proposal in terms of type-I error. We have generated
bivariate binary and time-to-event data through a copula-based framework and using conditional sampling as described
in (Trivedi and Zimmer, 2007). The parameters used for the simulation (summarized in Table 1) have been the
following: Frank’s copula with association parameter θ = 0.001, 2, 3; Weibull survival functions, S b,a(t) = e−(t/b)
a
,
with a = 0.5, 1, 2 and b = 1; probability of having the binary endpoint p(0) = 0.2, 0.4; and sample size per arm
n(i) = 1000.
The censoring distributions between groups were assumed equal and uniform U(0, c) with c = 1, 3. Two different
follow-up configurations were considered for τ0 < τb ≤ τ: (i) τ0 = 0, τb = 0.5, τ = 1; and (ii) τ0 = 0, τb = τ = 1. We
have considered the weights: Qˆ(t) = Gˆ(t−)η · Sˆ (t−)ρ · (1 − Sˆ (t−))γ with η, ρ, γ = 0, 1 and such that η + ρ + γ ≥ 1, and
(ωb, ωs) equal to (0.5, 0.5). For each scenario, we ran 1000 replicates and estimated the significance level (α = 0.05).
We note that the chosen values of the association parameter θ correspond to an increasing association between
the binary and time-to-event outcomes. Indeed, the values θ = 0.001, 2, 3 are equivalent to 0, 0.32, 0.45 in terms of
Spearman’s rank correlation coefficient between the marginal distributions of the binary and time-to-event outcomes.
We have not considered higher values of θ as they do not fulfill the condition that S (i)X (τ) > 0 (i = 0, 1).
We have performed all computations using the R software (Version 3.6.2), and on a computer with an Intel(R)
Core(TM) i7-6700 CPU, 3.40 GHz, RAM 8.00GB, 64bit operating system. The time required to perform the consid-
ered simulations was 52 hours.
7.2. Size properties
The empirical results show that the type I error is very close to the nominal level α = 0.05 across a broad range
of situations. The empirical size resulted in type I errors with a median of 0.049 and first and third quartiles of
0.043 and 0.055, respectively. Table 2 summarizes the results according to the parameters of the simulation study.
The results show that the L-statistics have the appropriate size and that are not specially influenced by the censoring
distribution neither by the selection of weights (η, ρ, γ). Figure 3 displays how the empirical sizes behave according
to the association parameter θ and the follow-up configuration τb. We observe that when τb = 1 the empirical size is
slightly small than 0.05.
We compare the performance of the pooled and unpooled variance estimation and notice that the empirical sizes
do not substantially differ between them.
8. Discussion
We have proposed a class of statistics for a two-sample comparison based on two different outcomes: one dichoto-
mous taking care, in most occasions, of short term effects, and a second one addressed to detect long term differences
in a survival endpoint. Such statistics test the equality of proportions and the equality of survival functions. The
approach combines a score test for the difference in proportions and a Weighted Kaplan-Meier test-based for the dif-
ference of survival functions. The statistics are fully non-parametric and α level for testing the null hypothesis of no
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effect on any of these two outcomes. The statistics in the L-class are appealing in situations when both outcomes are
relevant, regardless of how the follow-up periods of each outcome are, and even when the hazards are not proportional
with respect to the time-to-event outcome or in the presence of delayed treatment effects, albeit the survival curves
are supposed not to cross. We have incorporated weighted functions in order to control the relative relevance of each
outcome and to specify the type of survival differences that may exist between groups.
The testing procedure using the L-class of statistics satisfies a property called coherence that says that the non-
rejection of an intersection hypothesis implies the nonrejection of any sub-hypothesis it implies, i.e., Hs,0 and Hb,0
(Romano and Wolf, 2005). However, the testing procedure based on the L-class of statistics does not fulfill the con-
sonant property that states that the rejection of the global null hypothesis implies the rejection of at least one of its
sub-hypothesis. Bittman et al. ((2009)) faced the problem of how to combine tests into a multiple testing procedure
for obtaining a procedure that satisfies the coherence and consonance principles. An extension of this work to obtain
a testing procedure that satisfies both properties could be an important research line to consider.
This work has been restricted to those cases in which censoring does not prevent to assess the binary endpoint
response. We are currently working on a more general censoring scheme where the binary endpoint could be censored.
Last but not least, extensions to sequential and adaptive procedures in which the binary outcome could be tested at
more than one time-point remain open for future research.
Software
The source code to reproduce the results may be found online in the GitHub repository:
https://github.com/MartaBofillRoig/SurvBin.
Supplementary Material
Supplementary Material is available by contacting the authors.
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Table 1: Scenarios simulation study.
Parameter Value Parameter Value
p(0) 0.2, 0.4 a 0.5, 1, 2
b 1 c 1, 3
θ 0.001, 2, 3 n(i) (i = 0, 1) 1000
τb 0.5, 1 τ 1
ωb = ωs 0.5 η, ρ, γ (η + ρ + γ ≥ 1) 0, 1
Table 2: Median empirical size from 1000 replications.
Variance estimator
Pooled Unpooled
(τb, τ) (0.5, 1) 0.052 0.050
(1, 1) 0.046 0.047
θ 0.001 0.049 0.050
2 0.048 0.048
3 0.049 0.048
p(0) 0.2 0.049 0.049
0.4 0.049 0.048
a 0.5 0.052 0.050
1 0.048 0.049
2 0.046 0.047
c 1 0.049 0.049
3 0.049 0.048
(ρ, γ, η) (0,1,0) 0.048 0.049
(1,1,0) 0.049 0.049
(0,0,1) 0.048 0.048
(0,1,1) 0.050 0.049
(1,1,1) 0.048 0.050
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Time
Example 1. HIV therapeutic vaccination:
• Safety response (Binary outcome)
• Time to viral rebound (Time-to-event outcome)
Time
τb
End of the study τ
τ = τb 
τ0 = 0
τ0 = τb
Example 2. Immunotherapy trials:
• Objective response (Binary outcome)
• Overall survival (Time-to-event outcome)
0
Figure 1: Illustration of two different follow-up configurations, the red and blue arrows represent the time-frame for binary and time-to-event
outcomes, respectively. The red line goes from the study starts (at time-point 0) until the binary outcome is evaluated (τb). The blue (dashed) line
goes from the time-to-event information begins to be collected (τ0) to the end of the study (τ).
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Figure 2: Kaplan-Meier Curves for Overall Survival.
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Figure 3: Empirical size according to the θ and τb parameters.
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